Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navitoclax - AbbVie

Drug Profile

Navitoclax - AbbVie

Alternative Names: ABT-263; RG 7423; RG 7433

Latest Information Update: 04 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Genentech
  • Class Antineoplastics; Benzamides; Morpholines; Piperazines; Small molecules; Sulfones
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Myelofibrosis
  • Phase I Precursor cell lymphoblastic leukaemia-lymphoma
  • Discontinued Chronic lymphocytic leukaemia; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 01 Dec 2018 Efficacy and adverse events data from a phase I clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In adults, In children, Combination therapy, Second-line therapy or greater) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2018)
  • 19 Oct 2018 Efficacy data from the phase II MONAVI-1 trial in Ovarian cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 19 Jul 2018 AbbVie initiates an expanded-access programme for Cancer (NCT03592576)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top